An Effective Anti-Cancer Combination Therapy, with Substantially Reduced Side Effects

Tech ID: 20801 / UC Case 2010-482-0


An image guided effective anti-cancer therapy, with greatly reduced side effects, using liposomal copper doxorubicin.

Full Description

Researchers at the University of California, Davis have developed an effective local therapeutic strategy with substantially reduced side effects using a combination of doxorubicin (Dox) and copper (II). Cu-liposomes were loaded with Dox up to a maximum concentration of 0.6mg-drug/mg-lipid. UC Davis researchers have studied the efficacy of Cu-Dox liposomes and optimized the treatment strategy using the highly invasive and metastatic Met-1 tumor, a syngeneic model of human breast carcinoma. All animals receiving the combined therapy survived throughout the 28 day course of treatment and did not show any side effects. Significant tumor regression was accomplished by combining Cu-Dox liposomes with another drug and tumor insonation.


  • Anti-cancer combination therapy


  • Reduced side effects
  • Enhanced anti-tumor activity when combined with entire tumor insonation

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,844,656 12/19/2017 2010-482


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Ferrara, Katherine W.
  • Kheirolomoom, Azadeh

Other Information


Anti-cancer combination therapy, Image guided cancer therapy, Liposomal Copper Doxorubicin

Categorized As